FLT-PET could help predict outcome in head and neck cancer

April 4, 2013

Change in F-18 fluorothymidine (FLT) uptake on PET during early radiotherapy or chemoradiotherapy is a strong indicator of the long-term outcomes of head and neck cancer patients, according to a study published in the April issue of the Journal of Nuclear Medicine.

Dutch researchers found that better three-year disease-free survival was associated with a maximum standardized uptake value (SUVmax) decrease of at least 45%, as well as a gross tumor volume decrease matching at least the median, during the first two weeks of treatment.